France's FSI could invest 100M euros in biotechs

14 April 2009

The French government is actively considering the provision of funding for the biotechnology industry, which is hit by limited access to R&D  capital in the current economic downturn (see also page 2). Investment  in the sector fell 79% to 143.0 million euros ($190.4 million) in 2008,  the Marketletter's European correspondent reports.

The financing is expected to come via the country's Strategic  Investment Fund, the FSI, with early indications that the amount  available will be less than for the automobile parts manufacturers that  have received about 300.0 million euros so far. The FSI is  majority-owned by the French tax authority and is intended raise 20.0  billion euros to provide minority support to companies in sensitive  sectors of the economy. A total of 100.0 million euros is understood to  be the likely extent of support for the country's biotechnology  firms.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight